WallStSmart

Knowles Cor (KN)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Knowles Cor generates 137% more annual revenue ($614.10M vs $258.90M). KN leads profitability with a 9.1% profit margin vs -15.5%. KN earns a higher WallStSmart Score of 56/100 (C).

KN

Buy

56

out of 100

Grade: C

Growth: 6.7Profit: 6.0Value: 5.3Quality: 8.0
Piotroski: 7/9Altman Z: 1.94

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

KNSignificantly Overvalued (-25.1%)

Margin of Safety

-25.1%

Fair Value

$21.59

Current Price

$31.65

$10.06 premium

UndervaluedFair: $21.59Overvalued
ZEPPUndervalued (+48.8%)

Margin of Safety

+48.8%

Fair Value

$46.82

Current Price

$18.43

$28.39 discount

UndervaluedFair: $46.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KN3 strengths · Avg: 9.0/10
PEG RatioValuation
0.4310/10

Growing faster than its price suggests

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
15.8%8/10

15.8% revenue growth

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

KN3 concerns · Avg: 2.7/10
Altman Z-ScoreHealth
1.944/10

Grey zone — moderate risk

P/E RatioValuation
42.8x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-11.50M2/10

Negative free cash flow — burning cash

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : KN

The strongest argument for KN centers on PEG Ratio, Debt/Equity, Revenue Growth. Revenue growth of 15.8% demonstrates continued momentum. PEG of 0.43 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : KN

The primary concerns for KN are Altman Z-Score, P/E Ratio, Free Cash Flow. A P/E of 42.8x leaves little room for execution misses.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

KN profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor ELECTRONIC COMPONENTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

KN scores higher overall (56/100 vs 41/100) and 15.8% revenue growth. ZEPP offers better value entry with a 48.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Knowles Cor

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Knowles Corporation designs, manufactures and sells microacoustic, audio processing and precision device solutions for the mobile consumer electronics, communications, medical technology, defense, electric and industrial vehicle markets. The company is headquartered in Itasca, Illinois.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?